Intra-Cellular Therapies (ITCI) PT Raised to $62 at Cantor Fitzgerald on FDA Approval
Tweet Send to a Friend
Cantor Fitzgerald analyst Charles Duncan raised ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
